Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations (Q49721961)

22 February 2018

title

Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations (English)

1 reference

22 February 2018

main subject

chronic myeloid leukemia

0 references

15

Hagop Kantarjian

1 reference

22 February 2018

5

William Wierda

1 reference

22 February 2018

6

Gautam Borthakur

1 reference

22 February 2018

7

Tapan Kadia

1 reference

22 February 2018

4

Susan O'Brien

1 reference

22 February 2018

9

Farhad Ravandi

1 reference

22 February 2018

13

Elias Jabbour

1 reference

22 February 2018

10

Mary Beth Rios

1 reference

22 February 2018

12

Sherry Pierce

1 reference

22 February 2018

Guillermo Garcia-Manero

8

Guillermo Garcia-Manero

1 reference

22 February 2018

2

Jorge E Cortes

1 reference

22 February 2018

1

Kiran Naqvi

1 reference

22 February 2018

Raja Luthra

3

Raja Luthra

1 reference

22 February 2018

Sara Dellasala

11

Sara Dellasala

1 reference

22 February 2018

Keyur P Patel

14

Keyur Patel

1 reference

22 February 2018

publication date

20 February 2018

1 reference

22 February 2018

International Journal of Hematology

published in

1 reference

22 February 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

cites work

1 reference

12 December 2020

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

12 December 2020

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

12 December 2020

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia

1 reference

12 December 2020

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

1 reference

12 December 2020

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

1 reference

12 December 2020

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

1 reference

12 December 2020

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)

1 reference

12 December 2020

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)

1 reference

12 December 2020

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

12 December 2020

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

1 reference

12 December 2020

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

1 reference

12 December 2020

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib

1 reference

12 December 2020

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

1 reference

12 December 2020

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors

1 reference

12 December 2020

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

1 reference

12 December 2020

Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression

1 reference

12 December 2020

Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

1 reference

12 December 2020

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

1 reference

12 December 2020

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

1 reference

12 December 2020

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

1 reference

12 December 2020

Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.

1 reference

12 December 2020

10.1007/S12185-018-2422-6

Identifiers

DOI

1 reference

22 February 2018

Dimensions Publication ID

1101127739

0 references

Fatcat ID

release_uddtkgwhwbbvzbpvg4bcg7zh5a

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/uddtkgwhwbbvzbpvg4bcg7zh5a

24 November 2022

mapped directly with Wikidata item

1 reference

22 February 2018